Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05148676
Other study ID # 2021-5584-17843
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 1, 2020
Est. completion date April 10, 2021

Study information

Verified date December 2021
Source Aga Khan University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

There remains scarcity of literature regarding the patient's health status post-COVID-19 infection. This study analyzes the prevalence of residual symptoms and quality of life (QoL) after COVID-19.


Description:

An anonymous online survey was administrated in Pakistan from November 2020 to April 2021 in COVID-19 survivors. The questionnaire used the 12-Item Short Form Health Survey (SF-12) to assess mental and physical QoL. Multivariate linear regression was used to explore factors associated with mental and physical QoL scores. A total of 331 COVID-19 survivors participated in our survey. Around 42.0% of the cohort reported within 1-3 months of diagnosis of COVID-19. The common residual symptoms were body aches (39.9%), low mood (32.6%), and cough (30.2%). Better physical QoL was associated with being male (adjusted beta: 3.328) and having no residual symptoms (6.955). However, suffering from nausea/vomiting during initial COVID-19 infection (-4.026), being admitted to the ICU during COVID-19 infection (-9.164), and suffering from residual body aches (-5.209) and low mood (-2.959) was associated with poorer QoL. Better mental QoL was associated with being asymptomatic during initial COVID-19 infection (6.149) and post-COVID (6.685), while experiencing low mood post-COVID was associated with poorer mental QoL (-8.253 [-10.914, -5.592]). Despite presumed "recovery" from COVID-19, patients still face a wide range of residual symptoms months after initial infection, which contributes towards poorer QoL. Healthcare professionals must remain alert to the long-lasting effects of COVID-19 infection and aim to address them appropriately to improve patients' QoL.


Recruitment information / eligibility

Status Completed
Enrollment 331
Est. completion date April 10, 2021
Est. primary completion date April 1, 2021
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Tested negative for COVID-19 when enrolled in the study - COVID-19 negative for at least 6 months Exclusion Criteria: - Still Positive for COVID-19 tested one week ago - COVID-19 negative for less than 6 months

Study Design


Intervention

Other:
Residual Symptoms and the Quality of Life in Individuals Recovered from COVID-19 Infection: A Survey from Pakistan
An anonymous online survey was administrated in Pakistan from November 2020 to April 2021 in COVID-19 survivors. The questionnaire used the 12-Item Short Form Health Survey (SF-12) to assess mental and physical QoL. Multivariate linear regression was used to explore factors associated with mental and physical QoL scores.

Locations

Country Name City State
Pakistan Aga Khan University Karachi Sindh

Sponsors (1)

Lead Sponsor Collaborator
Aga Khan University

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Residual Symptoms and the Quality of Life in Individuals Recovered from COVID-19 Infection: A Survey from Pakistan The questionnaire used the 12-Item Short Form Health Survey (SF-12) to assess mental and physical QoL. Multivariate linear regression was used to explore factors associated with mental and physical QoL scores. November 2020 to April 2021
See also
  Status Clinical Trial Phase
Completed NCT05197634 - The Impact of Covid-19 Pandemic On The Children With Autism Spectrum Disorder
Recruiting NCT05918939 - UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study) Early Phase 1
Completed NCT05383560 - Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults Phase 2
Active, not recruiting NCT05125874 - Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization N/A
Completed NCT05517148 - Effects of an Immersive Virtual Reality Intervention Combined With Mindfulness-based Stress Reduction N/A
Completed NCT05552989 - Towards Better Preparedness for Future Catastrophes - Local Lessons-learned From COVID-19
Completed NCT05543551 - Effects of Diagrammatic Breathing With and Without Resistance in Post Covid Patients on ADLs N/A
Active, not recruiting NCT06272253 - UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects Early Phase 1
Active, not recruiting NCT05585567 - A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5 Early Phase 1
Active, not recruiting NCT05582746 - COVID-19 Testing and Vaccine Literacy for Women With Criminal Legal System Involvement N/A
Not yet recruiting NCT05381883 - Mental Health of Professionals of the Silver Economy of New Aquitaine : Online Survey of Accommodation Establishments for Old People and Home Assistance Establishments N/A
Recruiting NCT05062681 - RCT on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow Phase 4
Completed NCT04697030 - Burnout Among Adolescent Population During Covid-19 Lockdown in Pakistan
Active, not recruiting NCT05419167 - STEP-COVID: A Program for Pregnant Women During the SARS-CoV-2 Pandemic Phase 1
Terminated NCT05553964 - SARS-CoV-2 OTC At Home Test N/A
Completed NCT05596032 - Prospective Study to Validate the Diagnostic Performance of IVD CAPSULE COVID-19-NP Test for the Detection of SARS-CoV-2
Completed NCT05583812 - A Study of FB2001 for Inhalation in Healthy Chinese Adults Phase 1
Completed NCT05844410 - Evaluation of Corticosteroids Use and Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Study
Completed NCT05123573 - Self-Perceived in Medical Students Undergoing Distance Learning
Completed NCT05305300 - A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals Phase 1